Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dsx.2023.102851 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy of a Mobile Health-Based Behavioral Treatment for Lifestyle Modification in Type 2 Diabetes Self-Management: Greenhabit Randomized Controlled Trial.
J Med Internet Res
January 2025
Department of Internal Medicine, Hospital Clinic, Institut d'Investigacio Biomèdica August Pi i Sunyer, Barcelona, Spain.
Background: Enhancing self-management in health care through digital tools is a promising strategy to empower patients with type 2 diabetes (T2D) to improve self-care.
Objective: This study evaluates whether the Greenhabit (mobile health [mHealth]) behavioral treatment enhances T2D outcomes compared with standard care.
Methods: A 12-week, parallel, single-blind randomized controlled trial was conducted with 123 participants (62/123, 50%, female; mean age 58.
Effect of ozone oil and non-surgical periodontal treatment in patients with type 2 diabetes. In-vivo and in-vitro studies with fibroblasts and Candida albicans.
J Appl Oral Sci
January 2025
Universidade Federal Fluminense, Instituto de Saúde de Nova Friburgo, Departamento de Clínica Odontológica, Nova Friburgo, Rio de Janeiro, Brasil.
Aim: To evaluate the clinical effectiveness of ozonated sunflower oil (Oz) as an adjunctive of non-surgical periodontal therapy in patients with type 2 diabetes mellitus (DM2), on fibroblast cell viability and migration and the effectiveness of Oz on a Candida albicans (C. albicans) culture.
Methodology: In total, 32 sites in 16 DM2 with moderate to advanced periodontal disease with periodontal pocket depths ≥5mm were selected.
An anonymized, de-identified registry study protocol to determine the effectiveness and safety of weight loss with enavogliflozin in patients with type 2 diabetes mellitus.
PLoS One
January 2025
Department of Endocrinology and Metabolism, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
Sodium-glucose co-transporter 2 inhibitors, such as enavogliflozin, offer promising metabolic benefits for patients with type 2 diabetes (T2D), including glycemic control and improved cardiac function. Despite the clinical evidence, real-world evidence is needed to validate their safety and effectiveness. This study aims to evaluate the effects of weight loss and safety of enavogliflozin administration in patients with T2D in a real-world clinical setting over 24 weeks.
View Article and Find Full Text PDFAssociation of the combination of corporal adiposity and cardiorespiratory fitness with cardiometabolic risk factors in children - PREVOI Study.
Rev Paul Pediatr
January 2025
Universidade Federal do Espírito Santo, Programa de Pós-Graduação Nutrição e Saúde, Vitória, ES, Brazil.
Objective: To assess the association between the combination of corporal adiposity (CA) and cardiorespiratory physical fitness (CRF) with cardiometabolic risk factors in children aged 7-10 years.
Methods: Cross-sectional observational study with a sample of 251 children registered in Family Health Units. Sociodemographic, lifestyle, anthropometric, biochemical, blood pressure, and CRF data were collected.
Predicting the onset of chronic kidney disease (CKD) for diabetic patients with aggregated longitudinal EMR data.
PLOS Digit Health
January 2025
Department of Mathematics & Statistics, York University, Toronto, Canada.
Chronic kidney disease (CKD) affects over 13% of the population, totaling more than 800 million individuals worldwide. Timely identification and intervention are crucial to delay CKD progression and improve patient outcomes. This research focuses on developing a predictive model to classify diabetic patients showing signs of kidney function impairment based on their CKD development risk.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!